Cutera (CUTR) Stock Price, News & Analysis

Company Overview

Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

Key Stats

• Today's Range: $0.09 to $0.11
• 50-Day Range: $0.04 to $0.31
• 52-Week Range: $0.09 to $2.88
• Volume: 27.70 million shs
• Average Volume: 2.39 million shs
• Market Capitalization: $787,254.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Moderate Buy

Cutera Stock Analysis - MarketRank™

Cutera scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cutera has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cutera has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cutera are expected to grow in the coming year, from ($5.78) to ($3.98) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cutera is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cutera is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CUTR.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cutera does not currently pay a dividend.

Dividend Growth

Cutera does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CUTR.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Cutera this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cutera insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.42% of the stock of Cutera is held by insiders.

Percentage Held by Institutions

90.70% of the stock of Cutera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CUTR Stock Analysis - Frequently Asked Questions

How have CUTR shares performed this year?

Cutera's stock was trading at $0.3529 at the beginning of 2025. Since then, CUTR stock has decreased by 88.9% and is now trading at $0.0390.
View the best growth stocks for 2025 here.

How were Cutera's earnings last quarter?

Cutera, Inc. (NASDAQ:CUTR) released its quarterly earnings results on Thursday, November, 7th. The medical device company reported ($1.94) earnings per share for the quarter, missing the consensus estimate of ($0.96) by $0.98. The medical device company earned $32.50 million during the quarter, compared to analysts' expectations of $32.57 million.
Read the conference call transcript.

How do I buy shares of Cutera?

Shares of CUTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cutera own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cutera investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 5/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CUTR
• CIK: 1162461
• Web: www.cutera.com
• Phone: (415) 657-5500
• Fax: 415-330-2444
• Employees: 460
• Year Founded: 1998

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +7,592.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-162,830,000.00
• Net Margins: -84.86%
• Pretax Margin: -91.81%
• Return on Equity: N/A
• Return on Assets: -45.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.88
• Quick Ratio: 1.86

Sales & Book Value

• Annual Sales: $155.21 million
• Price / Sales: 0.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($8.62) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 20,186,000
• Free Float: 20,101,000
• Market Cap: $787,254.00
• Optionable: Optionable
• Beta: 1.36